Cover Image
Market Research Report

Prescription Dermatology Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Published by Transparency Market Research Product code 763054
Published Content info 183 Pages
Delivery time: 1-2 business days
Price
Back to Top
Prescription Dermatology Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
Published: November 14, 2018 Content info: 183 Pages
Description

Title:
Prescription Dermatology Therapeutics Market (Product Type - Acne and Rosacea Drugs, Psoriasis Drugs, Dermatitis and Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Prescription Dermatology Therapeutics Market - Overview

This report by Transparency Market Research analyzes the global prescription dermatology therapeutics market for the period between 2018 and 2026. An in-depth and unbiased market assessment has been made which offers readers an in-depth and accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in research & development, manufacture, and marketing of products prescribed in the treatment of various skin conditions.

The global prescription dermatology therapeutics market has been studied for the forecast period from 2018 to 2026. For research, 2017 has been considered as the base year and 2016 as the historical year. The global prescription dermatology therapeutics market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape, by major players operating in this market along with their shares (value %) of the global prescription dermatology therapeutics market for 2017. The report also provides detailed company profiles of emerging market players operating in the global prescription dermatology therapeutics market.

The market overview section comprises impact factors such as key market dynamics including drivers, restraints, and opportunities, affecting the global prescription dermatology therapeutics market. These factors are likely to aid stakeholders establish a strong foothold in the global prescription dermatology therapeutics market. Furthermore, the market overview section comprises key industry events, pipeline analysis, key mergers & acquisitions across the dermatology industry, epidemiology analysis of the skin diseases, product portfolio overview of leading players, and market attractiveness analysis in the global prescription dermatology therapeutics market. The market attractiveness analysis provides a graphical view comparing the expansion and market dynamics in various segments and countries to identify the most attractive market.

Scope

The global prescription dermatology therapeutics market has been segmented based product type, distribution channel, and region. In terms of product type, the global market has been classified into acne & rosacea drugs, psoriasis drugs, dermatitis & seborrhea drugs, fungal infection drugs, skin cancer, and others. In terms of distribution channel, the global prescription dermatology therapeutics market has been categorized into hospital pharmacies, retail pharmacies, and mail order pharmacies.

In terms of region, the global prescription dermatology therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, quantitative analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, and Australia & New Zealand has also been provided in the report. A detailed qualitative analysis of factors responsible for driving and restraining the global market in various regions has been provided in this section.

The report provides a detailed outline/blueprint of the global prescription dermatology therapeutics market which is expected to assist new companies establish their presence and companies to expand their share in the market. The report concludes with the company profiles section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments of key players.

Competitive landscape

Major players operating in the global prescription dermatology therapeutics market include AbbVie, Inc., Janssen Biotech, Inc., Novartis AG, Amgen, Inc., Celgene Corporation, Pfizer, Inc., LEO Pharma A/S, Eli Lilly and Company, Bausch Health Companies, Inc., Sun Pharmaceuticals Ltd., Aclaris Therapeutics, Inc., and Aurobindo Pharma Ltd.

The global prescription dermatology therapeutics market has been segmented into:

  • Global Prescription Dermatology Therapeutics Market, by Product Type
  • Acne & Rosacea Drugs
  • Psoriasis Drugs
  • Dermatitis & Seborrhea Drugs
  • Fungal Infection Drugs
  • Skin Cancer Drugs
  • Others
  • Global Prescription Dermatology Therapeutics Market, by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies
  • Global Prescription Dermatology Therapeutics Market, by Region
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa
Table of Contents

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Prescription Dermatology Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, 2016-2026
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

  • 5.1.Pipeline Analysis
  • 5.2.Key Mergers & Acquisitions
  • 5.3.Disease Prevalence & Incidence Rate globally with key countries

6. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Product Type, 2016-2026
    • 6.3.1. Acne & Rosacea Drugs
    • 6.3.2. Psoriasis Drugs
    • 6.3.3. Dermatitis & Seborrhea Drugs
    • 6.3.4. Fungal Infection Drugs
    • 6.3.5. Skin Cancer Drugs
    • 6.3.6. Others
  • 6.4. Market Attractiveness, by Product Type

7. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2016-2026
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Mail Order Pharmacies
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Prescription Dermatology Therapeutics Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Country/Region

9. North America Prescription Dermatology Therapeutics Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Product Type, 2016-2026
    • 9.2.1. Acne & Rosacea Drugs
    • 9.2.2. Psoriasis Drugs
    • 9.2.3. Dermatitis & Seborrhea Drugs
    • 9.2.4. Fungal Infection Drugs
    • 9.2.5. Skin Cancer Drugs
    • 9.2.6. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2016-2026
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Mail Order Pharmacies
  • 9.4. Market Value Forecast, by Country, 2016-2026
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Product Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Prescription Dermatology Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Product Type, 2016-2026
    • 10.2.1. Acne & Rosacea Drugs
    • 10.2.2. Psoriasis Drugs
    • 10.2.3. Dermatitis & Seborrhea Drugs
    • 10.2.4. Fungal Infection Drugs
    • 10.2.5. Skin Cancer Drugs
    • 10.2.6. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2016-2026
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Mail Order Pharmacies
  • 10.4. Market Value Forecast, by Country/Sub-region, 2016-2026
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Product Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Prescription Dermatology Therapeutics Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Key Findings
  • 11.2.Market Value Forecast, by Product Type, 2016-2026
    • 11.2.1. Acne & Rosacea Drugs
    • 11.2.2. Psoriasis Drugs
    • 11.2.3. Dermatitis & Seborrhea Drugs
    • 11.2.4. Fungal Infection Drugs
    • 11.2.5. Skin Cancer Drugs
    • 11.2.6. Others
  • 11.3.Market Value Forecast, by Distribution Channel, 2016-2026
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Mail Order Pharmacies
  • 11.4.Market Value Forecast, by Country/Sub-region, 2016-2026
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5.Market Attractiveness Analysis
    • 11.5.1. By Product Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Prescription Dermatology Therapeutics Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Key Findings
  • 12.2.Market Value Forecast, by Product Type, 2016-2026
    • 12.2.1. Acne & Rosacea Drugs
    • 12.2.2. Psoriasis Drugs
    • 12.2.3. Dermatitis & Seborrhea Drugs
    • 12.2.4. Fungal Infection Drugs
    • 12.2.5. Skin Cancer Drugs
    • 12.2.6. Others
  • 12.3.Market Value Forecast, by Distribution Channel, 2016-2026
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. Mail Order Pharmacies
  • 12.4.Market Value Forecast, by Country/Sub-region, 2016-2026
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5.Market Attractiveness Analysis
    • 12.5.1. By Product Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Prescription Dermatology Therapeutics Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Key Findings
  • 13.2.Market Value Forecast, by Product Type, 2016-2026
    • 13.2.1. Acne & Rosacea Drugs
    • 13.2.2. Psoriasis Drugs
    • 13.2.3. Dermatitis & Seborrhea Drugs
    • 13.2.4. Fungal Infection Drugs
    • 13.2.5. Skin Cancer Drugs
    • 13.2.6. Others
  • 13.3 Market Value Forecast, by Distribution Channel, 2016-2026
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. Mail Order Pharmacies

13.4.Market Value Forecast, by Country/Sub-region, 2016-2026

    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
    • 13.5.Market Attractiveness Analysis
    • 13.5.1. By Product Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1.Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2.Market Share Analysis By Company (2017)
  • 14.3. Company Profiles
    • 14.3.1. AbbVie, Inc.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Janssen Biotech, Inc.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Novartis AG
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Amgen, Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Celgene Corporation
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Pfizer, Inc.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. LEO Pharma A/S
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Eli Lilly and Company
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Bausch Health Companies, Inc.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Sun Pharmaceuticals Ltd.
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Aclaris Therapeutics, Inc.
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. SWOT Analysis
      • 14.3.11.4. Financial Overview
      • 14.3.11.5. Strategic Overview
    • 14.3.12. Aurobindo Pharma Ltd
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Product Portfolio
      • 14.3.12.3. SWOT Analysis
      • 14.3.12.4. Financial Overview
      • 14.3.12.5. Strategic Overview
  • Table 01: Global Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2016-2026
  • Table 02: Global Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 03: Global Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016-2026
  • Table 04: North America Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • Table 05: North America Prescription Dermatology Therapeutics Value (US$ Mn) Forecast, by Product Type, 2016-2026
  • Table 06: North America Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 07: Europe Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 08: Europe Prescription Dermatology Therapeutics Value (US$ Mn) Forecast, by Product, 2016-2026
  • Table 09: Europe Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 10: Asia Pacific Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 11: Asia Pacific Prescription Dermatology Therapeutics Value (US$ Mn) Forecast, by Product Type, 2016-2026
  • Table 12: Asia Pacific Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 13: Latin America Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 14: Latin America Prescription Dermatology Therapeutics Value (US$ Mn) Forecast, by Product Type, 2016-2026
  • Table 15: Latin America Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 16: Middle East & Africa Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 17: Middle East & Africa Prescription Dermatology Therapeutics Value (US$ Mn) Forecast, by Product, 2016-2026
  • Table 18: Middle East & Africa Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Figure 01: Global Prescription Dermatology Therapeutics Market Snapshot
  • Figure 02: Global Fluid Management Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025
  • Figure 03: Global Prescription Dermatology Therapeutics Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 05: Global Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel (2017)
  • Figure 06: Global Prescription Dermatology Therapeutics Market Value Share (%), by Region (2017)
  • Figure 04: Global Prescription Dermatology Therapeutics Market Value Share (%), by Product Type (2017)
  • Figure 07: Global Prescription Dermatology Therapeutics Market Value Share Analysis, by Product Type, 2017 and 2026
  • Figure 08: Global Prescription Dermatology Therapeutics Market Attractiveness, by Product Type, 2018-2026
  • Figure 09: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Acne & Rosacea Drugs, 2016-2026
  • Figure 10: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Psoriasis Drugs, 2016-2026
  • Figure 11: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dermatitis & Seborrhea Drugs, 2016-2026
  • Figure 12: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fungal Infection Drugs, 2016-2026
  • Figure 13: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Skin Cancer Drugs, 2016-2026
  • Figure 14: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016-2026
  • Figure 15: Global Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 17: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016-2026
  • Figure 18: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Mail Order Pharmacies, 2016-2026
  • Figure 16: Global Prescription Dermatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016-2026
  • Figure 19: Global Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 20: Global Prescription Dermatology Therapeutics Market Value Share Analysis, by Region 2017 and 2026
  • Figure 21: Global Prescription Dermatology Therapeutics Market Attractiveness, by Region, 2018-2026
  • Figure 22: North America Prescription Dermatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 23: North America Prescription Dermatology Therapeutics Market Value Share (%), by Country, 2017 and 2026
  • Figure 24: North America Prescription Dermatology Therapeutics Market Attractiveness, by Country, 2018-2026
  • Figure 25: North America Prescription Dermatology Therapeutics Market Value Share (%), by Product Type, 2017 and 2026
  • Figure 26: North America Prescription Dermatology Therapeutics Market Attractiveness, by Product Type, 2018-2026
  • Figure 27: North America Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 28: North America Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 29: Europe Prescription Dermatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 30: Europe Prescription Dermatology Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 31: Europe Prescription Dermatology Therapeutics Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 32: Europe Prescription Dermatology Therapeutics Market Value Share (%), by Product, 2017 and 2026
  • Figure 33: Europe Prescription Dermatology Therapeutics Market Attractiveness, by Product, 2018-2026
  • Figure 34: Europe Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 35: Europe Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 36: Asia Pacific Prescription Dermatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 37: Asia Pacific Prescription Dermatology Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 38: Asia Pacific Prescription Dermatology Therapeutics Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 39: Asia Pacific Prescription Dermatology Therapeutics Market Value Share (%), by Product Type, 2017 and 2026
  • Figure 40: Asia Pacific Prescription Dermatology Therapeutics Market Attractiveness, by Product Type, 2018-2026
  • Figure 41: Asia Pacific Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 42: Asia Pacific Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 43: Latin America Prescription Dermatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 44: Latin America Prescription Dermatology Therapeutics Market Value Share (%), by Country/Sub-region 2017 and 2026
  • Figure 45: Latin America Prescription Dermatology Therapeutics Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 46: Latin America Prescription Dermatology Therapeutics Market Value Share (%), by Product Type, 2017 and 2026
  • Figure 47: Latin America Prescription Dermatology Therapeutics Market Attractiveness, by Product Type, 2018-2026
  • Figure 48: Latin America Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 49: Latin America Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 50: Middle East & Africa Prescription Dermatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 51: Middle East & Africa Prescription Dermatology Therapeutics Market Value Share (%), by Country/Sub-region 2017 and 2026
  • Figure 52: Middle East & Africa Prescription Dermatology Therapeutics Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 53: Middle East & Africa Prescription Dermatology Therapeutics Market Value Share (%), by Product, 2017 and 2026
  • Figure 54: Middle East & Africa Prescription Dermatology Therapeutics Market Attractiveness, by Product, 2018-2026
  • Figure 55: Middle East & Africa Prescription Dermatology Therapeutics Market Value Share (%), by Distribution Channel, 2017 and 2026
  • Figure 56: Middle East & Africa Prescription Dermatology Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 57: Global Prescription Dermatology Therapeutics Market Share Analysis, by Company (2017)
  • Figure 58: AbbVie, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2017
  • Figure 59: AbbVie, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2015-2016
  • Figure 60: AbbVie, Inc. Breakdown of Net Sales (%), by Region
  • Figure 61: Janssen Biotech, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2017
  • Figure 62: Breakdown of Net Sales (%), by Business Segment, (2017)
  • Figure 63: Janssen Biotech, Inc. Breakdown of Net Sales (%), by Geography (2017)
  • Figure 64: Janssen Biotech, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2016-2017
  • Figure 65: Janssen Biotech, Inc. Breakdown of Net Sales, by Geography (2017)
  • Figure 66: Janssen Biotech, Inc. Breakdown of Net Sales, by Business Segment (2017)
  • Figure 67: Janssen Biotech, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2016-2017
  • Figure 68: Janssen Biotech, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2017
  • Figure 69: Amgen, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2016-2017
  • Figure 70: Amgen, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2017
  • Figure 71: Amgen, Inc. Breakdown of Net Sales, by Region, 2017
  • Figure 72: Celgene Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 73: Celgene Corporation Breakdown of Net Sales (%), by Key Product (2017)
  • Figure 74: Celgene Corporation R&D Intensity and Sales & Marketing Intensity - Company Level, 2016-2017
  • Figure 75: Celgene Corporation Breakdown of Net Sales, by Geography (2017)
  • Figure 76; Pfizer, Inc. Breakdown of Net Sales, by Region, 2017
  • Figure 78: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2016-2017
  • Figure 79: LEO Pharma A/S Breakdown of Net Sales, by Geography (2017)
  • Figure 80: LEO Pharma A/S Breakdown of Net Sales, by Therapeutic Area (2017)
  • Figure 81: LEO Pharma A/S Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 82; Eli Lilly and Company Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 83; Eli Lilly and Company Breakdown of Net Sales (%), by Region, 2017
  • Figure 84 Eli Lilly and Company Research & Development Cost (US$ Mn), 2016 and 2017
  • Figure 85: Eli Lilly and Company Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 86: Bausch Health Companies, Inc. R&D Expenses (US$ Mn), 2015-2017
  • Figure 87: Bausch Health Companies, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2017
  • Figure 88: Bausch Health Companies, Inc. Breakdown of Net Sales (%), by Region, 2016
  • Figure 89: Allergan plc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2016-2017
  • Figure 90: Allergan plc. Breakdown of Net Sales, by Business Segment (2017)
  • Figure 91: Allergan plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2017
  • Figure 92: Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Geography (2017)
  • Figure 93: Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Business Segment (2017)
  • Figure 94: Sun Pharmaceuticals Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 95: Aclaris Therapeutics, Inc. R&D Expenses (US$ Mn), 2013-2016
  • Figure 96: Aurobindo Pharma Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014-2017
  • Figure 97: Aurobindo Pharma Ltd. Breakdown of Net Sales, by Business Segment (2017)
Back to Top